Current Targets For CAR-T Therapy Used in Experiments for The Treatment of Thoracic Cancer
DOI:
https://doi.org/10.54097/7p98w417Keywords:
Chimeric antigen receptor therapy; Lung cancer; Breast cancer.Abstract
Cancer can progress rapidly and cause death within months. Methods of treatment have merited attention. Cart-t cell treatment has been proven to be an emerging approach towards malignant tumours. Until now, successful results have been showing in treating blood tumours while targets or drugs for solid tumours are still under experiments. In this article, some common and potential targets for better treatment effects against thoracic cancer have been introduced. Thoracic cancer consists of those malignant tumours that originate in the chest cavity, including lung cancer and breast cancer.
Downloads
References
Ferlay J, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer, 2020.
The American Cancer Society medical and editorial content team. Lifetime Risk of Developing or Dying From Cancer, January 12, 2023.
Zijun Zhao, et al. The application of CAR-T cell therapy in haematological malignancies: advantages and challenges. Acta Pharm Sin B, 2018, 8(4): 539–551.
Carl H June, Michel Sadelain. Chimeric Antigen Receptor Therapy. N Engl J Med, 2018, 379(1): 64-73.
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma, March 26, 2021.
Luisa Chocarro, et al. CAR-T Cells for the Treatment of Lung Cancer. Life (Basel), 2022, 12(4): 561.
Long Chen, et al. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer, 2022, 13(7): 889-899.
Maysoon Al-Haideri, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int, 2022, 22: 365.
Yujing Xuan, et al. Targeting CD276 by CAR-T cells induces regression of oesophagus squamous cell carcinoma in xenograft mouse models. Transl Oncol, 2021, 14(8): 101138.
Pouya Safarzadeh Kozani, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res, 2022, 10(1): 24.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
